Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy

Figure 6

Mechanistic investigations indicated that anti-PD-L1 antibody augmented T cell immune response and alleviated the tolerance of BC to radiotherapy by regulating the miR-21/PDCD4/PI3K/Akt/PD-L1 axis.